[5] In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin.

[7] A study published in September 2020, found that ertugliflozin to be essentially non-inferior to placebo with respect to cardiovascular events.

[4] A systematic review and meta-analysis of ertugliflozin, published in 2024, found it to have a good glycemic efficacy and a reassuring safety profile in managing type 2 diabetes.

[13] Under the US approval, ertugliflozin is contraindicated for people with severe kidney failure, end-stage renal disease, and dialysis.

[7] Adverse effects in studies that were significantly more common under ertugliflozin than under placebo included mycosis of the genitals in both men and women, vaginal itch, increased urination, thirst, hypoglycaemia (low blood sugar), and weight loss under the higher dosing scheme.